Effects of Short-Term Statins Pre-treatment on Reperfusion and Short-Term Clinical Prognosis after Percutanous Coronary Intervention in Patients with Non ST-segment Elevation Acute Coronary Syndrome

Objective To evaluate the effect of short-term pre-treatment with statins on the reperfusion and short-term clinical prognosis in patients with non ST-segment elevation acute coronary syndrome(NSTE-ACS) who underwent successful primary percutanous coronary intervention (PCI).Methods A total of 162 consecutive high-risk NSTE-ACS patients undergoing PCI within 72 hours were randomly divided into two groups:standard statin group received 20 mg simvastatin and intensive statin group received 80 mg simvastatin for 3 days before PCI.The difference of thrombolysis in myocardial infarction (TIMI) and myocardial blush grade (MBG)of target arteries before and after PCI,serum level of CK-MB at 24h,left ventricular ejection fraction (LVEF) and the incidence of main adverse cardiac events (MACE) at 30-day follow-up were examined in the 2 groups.Results The difference in basic clinical data between the two groups showed no statistical significance (P0.05).The percentage of TIMI grade 2-3 flow and MBG 2-3 perfusion were significantly higher in intensive statin group than those in standard statin group before PCI (P0.05).The TIMI grade 3 flow in intensive statin group showed similar result to that in standard statin group after PCI (P0.05),but the percentage of MBG 2-3 perfusion in intensive statin group was significantly higher than that in standard statin group(P0.05).The incidence of increased CK-MB in intensive statin group was significantly lower than that in standard statin group(P0.05).One month after PCI the LVEF in intensive statin group [(0.58±0.09)%] was higher than that in standard statin group [(0.53±0.08)%](P0.05).The incidence of MACE (P0.05) in intensive statin group was also lower than that in standard statin group.Conclusion Pre-treatment with short-term statin of high-dose before PCI could improve the PCI postoperative coronary flow,myocardial perfusion and heart function,attenuate the risk of MACE in high-risk NSTE-ACS patients.